Muhammad Ibrahim RAJOKA, Shazia Anwer BUKHARI, Kashaf ZAFAR, Zubair IBRAHIM, Sadia JAVED, Rafshan SADIQ

Oxidative stress-induced DNA damage and homocysteine accumulation may beinvolved in ovarian cancer progression in both young and old patients

Background/aim: Biochemical, environmental, and genetic factors such as oxidative stress-induced DNA damage and homocysteine (Hcy) accumulation in the blood are involved in the development and progression of ovarian cancer. This study measured some biomarkers closely linked to the progression of ovarian cancer and also found their correlates. Materials and methods: Thirty patients were diagnosed with ovarian cancer using pelvic examination, transvaginal ultrasound, and cancer antibody (CA-125) measurement. Total oxidative stress (TOS), DNA damage, Hcy, malondialdehyde (MDA), total antioxidant status (TAS), and other biochemical parameters were determined. Results: TOS and DNA damage were positively and significantly correlated between themselves and were involved in causation of tumors as reflected by significantly (P < 0.001) higher CA-125, erythrocyte sedimentation rate (ESR), creatinine, and C-reactive protein (CRP) in both young and old patients. Both were significantly correlated with Hcy, LDL-cholesterol, alanine aminotransferase, aspartate aminotransferase, CRP, MDA, and CA-125. However, they were negatively correlated with TAS. Thus, excessive inflammation and oxidative stress caused an increase in DNA damage and enhanced Hcy content, leading to development of ovarian cancer. Conclusion: This study suggests the use of antioxidants as drugs to reduce oxidative stress, DNA damage, and other causes of cancer development

PDF

___

1. Nossov V. The early detection of ovarian cancer: from traditional methods to proteomics. Can we really do better than serum ca-125? Am J Obstet Gynecol 2008; 23: 199-215.
2. Bhurgri Y, Bhurgri A, Hassan SH. Cancer incidence in Karachi, Pakistan: first results from Karachi cancer registry. Int J Cancer 2000; 85: 325-329.
3. Bhurgri Y. Karachi cancer registry dataimplications for the National Cancer Control Program of Pakistan. Asian Pac J Cancer P 2004; 5: 77-82.
4. Valko M, Rhodes CJ, Monocol J. Free radicals, metals and anti-oxidants in oxidative stress-induced cancer. Chem-Biol Interact 2006; 160: 1-40
5. Klaunig JE, Kamendulis LM. The role of oxidative stress in carcinogenesis. Annu Rev Pharmacol 2004; 44: 239-267.
6. Senthil K, Aranganathan S, Nalini N. Evidence of oxidative stress in the circulation of ovarian cancer patients. Clin Chim Acta 2004; 339: 27-32.
7. Corona G, Toffoli G, Fabris M, Viel A, Zarrelli A, Donada C, Boiocchi M. Homocysteine accumulation in human ovarian carcinoma ascitic/cystic fluids possibly caused by metabolic alteration of the methionine cycle in ovarian carcinoma cells. Eur J Cancer 2007; 27: 1185-1189.
8. Chung MK, Martin DO, Sprecher D, Wazni O, Kanderian A, Carnes CA, Bauer JA, Tchou PJ, Niebauer M, Natale A et al. C-reactive protein elevation in patients with atrial arrhythmias: inflammatory mechanisms and persistence of atrial fibrillation. Circulation 2001; 104: 2886-2891.
9. Erel O. A new automated colorimetric method for measuring total oxidant status. Clin Biochem 2005; 38: 1103-1111.
10. Sciskalka M, Zalewska M, Grzelak A, Milnerowicz H. The influence of the occupational exposure to heavy metals and tobacco smoke on the selected oxidative stress markersin smelters. Biol Trace Elem Res 2014; 159: 59-68.
11. Steel RGD, Torrie JH, Dickey DA. Principles and Procedures of Statistics: A Biometrical Approach. 3rd ed. New York, NY, USA: McGraw Hill; 1999.
12. Duncan DB (1955). Multiple range and multiple F tests. Biometrics 11: l-42.
13. Bandebuche S, Melinkeri RR. Oxidative stress and antioxidant status in patients of ovarian cancer. Biomed Res-India 2010; 22: 93-197.
14. Mori M, Nishida T, Sugiyama T. Anthropometric and other risk factors for ovarian cancer in a case-control study. Jpn J Cancer Res 1998; 89: 246-253.
15. Greggi S, Parazzini F, Paratore MP. Risk factors for ovarian cancer in central Italy. Gynecol Oncol 2000; 79: 50-54.
16. Lambe M, Wigertz A, Garmo H, Walldius G, Jungner I, Hammar N. Impaired glucose metabolism and diabetes and the risk of breast, endometrial, and ovarian cancer. Cancer Cause Control 2011; 22: 1163-1171.
17. Ness RB, Cottreau C. Possible role of ovarian epithelial inflammation in ovarian cancer. J Natl Cancer I 1999; 91: 1459- 1467.
18. Mcsorley MA, Alberg AJ, Allen DS, Allen NE, Brinton LA, Dorgan JF, Pollak M, Tao Y, Helzlsouer KJ. C-reactive protein concentrations and subsequent ovarian cancer risk. Obstet Gynecol 2007; 109: 933-941.
19. Osman N, Oleary N, Mulcahy E, Barrett N, Wallis F, Hickey K, Gupta R. Correlation of serum CA125 with stage, grade and survival of patients with epithelial ovarian cancer at a single centre. Irish Med J 2008; 101: 245-247.
20. Memon NQ, Memon JQ, Khan AW. Serum cholesterol levels and incidence of ovarian tumours in Pakistani women. Pak J Physiol 2007; 3: 23.